These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 9609245)
1. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli--a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli. Randolph MM; White GL; Kosanke SD; Bild G; Carr C; Galluppi G; Hinshaw LB; Taylor FB Thromb Haemost; 1998 May; 79(5):1048-53. PubMed ID: 9609245 [TBL] [Abstract][Full Text] [Related]
2. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Carr C; Bild GS; Chang AC; Peer GT; Palmier MO; Frazier RB; Gustafson ME; Wun TC; Creasey AA; Hinshaw LB Circ Shock; 1994 Nov; 44(3):126-37. PubMed ID: 7600636 [TBL] [Abstract][Full Text] [Related]
4. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Hinshaw LB; Tekamp-Olson P; Chang AC; Lee PA; Taylor FB; Murray CK; Peer GT; Emerson TE; Passey RB; Kuo GC Circ Shock; 1990 Mar; 30(3):279-92. PubMed ID: 2178801 [TBL] [Abstract][Full Text] [Related]
5. Retrospective description and experimental reconstitution of three different responses of the baboon to lethal E. coli. Taylor FB; Kosanke S; Randolph M; Emerson T; Hinshaw LB; White GL; Chang AC; Peer G; Blick K Circ Shock; 1994 Feb; 42(2):92-103. PubMed ID: 8013066 [TBL] [Abstract][Full Text] [Related]
6. Prevention or amelioration of morphologic lesions in LD100 E coli-shocked baboons with steroid/antibiotic therapy. Archer LT; Kosanke SD; Beller BK; Passey RB; Hinshaw LB Adv Shock Res; 1983; 10():195-215. PubMed ID: 6349298 [TBL] [Abstract][Full Text] [Related]
7. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Taylor FB; Chang AC; Peer G; Li A; Ezban M; Hedner U Blood; 1998 Mar; 91(5):1609-15. PubMed ID: 9473226 [TBL] [Abstract][Full Text] [Related]
8. Retrospective study comparing the pathophysiology of antibiotic-treated and untreated Escherichia coli- and Staphylococcus aureus-infused baboons. He S; Hinshaw L; Emerson T; Kosanke S; White G; Randolph MM; Chang AK; Duerr M; Peer G; Passey R Circ Shock; 1993 Oct; 41(2):88-102. PubMed ID: 8242885 [TBL] [Abstract][Full Text] [Related]
9. Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Taylor FB Prog Clin Biol Res; 1994; 388():175-94. PubMed ID: 7831358 [TBL] [Abstract][Full Text] [Related]
10. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Sabharwal AK; Bajaj SP; Ameri A; Tricomi SM; Hyers TM; Dahms TE; Taylor FB; Bajaj MS Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 1):758-67. PubMed ID: 7881667 [TBL] [Abstract][Full Text] [Related]
11. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Taylor FB; Emerson TE; Jordan R; Chang AK; Blick KE Circ Shock; 1988 Nov; 26(3):227-35. PubMed ID: 3061681 [TBL] [Abstract][Full Text] [Related]
13. Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. Schirm S; Liu X; Jennings LL; Jedrzejewski P; Dai Y; Hardy S J Infect Dis; 2009 Jun; 199(12):1807-15. PubMed ID: 19456231 [TBL] [Abstract][Full Text] [Related]
14. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Matyal R; Vin Y; Delude RL; Lee C; Creasey AA; Fink MP Intensive Care Med; 2001 Aug; 27(8):1274-80. PubMed ID: 11511939 [TBL] [Abstract][Full Text] [Related]
15. Escherichia coli shock in the baboon and the response to adrenocorticosteroid treatment. Hinshaw LB; Coalson JJ; Benjamin BA; Archer LT; Beller BK; Kling OR; Hasser EM; Phillips RW Surg Gynecol Obstet; 1978 Oct; 147(4):545-57. PubMed ID: 100890 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of treatment with the iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherichia coli. Molina L; Studenberg S; Wolberg G; Kazmierski W; Wilson J; Tadepalli A; Chang AC; Kosanke S; Hinshaw L J Clin Invest; 1996 Jul; 98(1):192-8. PubMed ID: 8690793 [TBL] [Abstract][Full Text] [Related]
17. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790 [TBL] [Abstract][Full Text] [Related]
18. Relationship of serum gentamicin levels and methylprednisolone sodium succinate treatment in baboons challenged with Escherichia coli LD100. Flournoy DJ; Beller BK; Archer LT; Hinshaw LB Clin Ther; 1983; 5(4):417-21. PubMed ID: 6347383 [TBL] [Abstract][Full Text] [Related]
19. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195 [TBL] [Abstract][Full Text] [Related]
20. Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2. Rao CN; Reddy P; Reeder DJ; Liu Y; Stack SM; Kisiel W; Woodley DT Biochem Biophys Res Commun; 2000 Oct; 276(3):1286-94. PubMed ID: 11027624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]